Stockscreener 앱 받기
4.75
5.32%
0.24
시간 외 거래:
4.67
-0.08
-1.68%
전일 마감가:
$4.51
열려 있는:
$4.585
하루 거래량:
387.52K
Relative Volume:
0.44
시가총액:
$337.96M
수익:
$14.20M
순이익/손실:
$-49.59M
주가수익비율:
-5.6387
EPS:
-0.8424
순현금흐름:
$-35.25M
1주 성능:
+1.93%
1개월 성능:
+35.71%
6개월 성능:
+176.16%
1년 성능:
+320.35%
1일 변동 폭
$4.56
$4.79
1주일 범위
$4.3203
$4.79
52주 변동 폭
$0.65
$5.30
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.75 | 320.88M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | Oppenheimer | Outperform |
| 2026-01-20 | 개시 | BTIG Research | Buy |
| 2025-12-10 | 개시 | B. Riley Securities | Buy |
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2025-10-29 | 개시 | Wedbush | Outperform |
| 2025-10-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-11 | 개시 | Craig Hallum | Buy |
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
모두보기
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Sahm
Loss Report: Will Opus Genetics Inc benefit from current market trends2026 Bull vs Bear & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Opus Genetics (IRD) 2026 proxy seeks director votes and doubling of authorized shares - Stock Titan
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch - TipRanks
Abu Dhabi launches UAE’s first gene therapy clinical trial - TradingView
Fed Meeting: Is Opus Genetics Inc attractive for institutional investorsCPI Data & AI Driven Price Forecasts - baoquankhu1.vn
Opus Genetics (IRD) to Release Earnings on Monday - MarketBeat
Gains Report: Is Opus Genetics Inc a strong growth stock2026 Analyst Calls & Technical Pattern Based Signals - baoquankhu1.vn
OCUP SEC FilingsOcuphire Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Opus Genetics COO Schachle sells $19,525 in stock By Investing.com - Investing.com India
Opus Genetics, Inc. (IRD) reports Q4 loss, tops revenue estimates - MSN
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells 2,816 Shares of Stock - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells $19,041.28 in Stock - MarketBeat
Opus Genetics COO Schachle sells $19,525 in stock - Investing.com
Insider Selling: Opus Genetics (NASDAQ:IRD) CEO Sells 24,438 Shares of Stock - MarketBeat
Opus Genetics chief scientific officer sells $19k in stock - Investing.com
Opus Genetics (IRD) COO covers tax withholding via 3,719-share sale - Stock Titan
Opus Genetics (IRD) officer has 2,816 shares sold to cover tax - Stock Titan
Opus Genetics (IRD) CEO has shares sold automatically to cover RSU taxes - Stock Titan
Opus Genetics (IRD) CSO has shares sold automatically for tax withholding - Stock Titan
Aug Catalysts: Can Opus Genetics Inc reach all time highs this yearMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Oppenheimer initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Up 17.9% in February - MarketBeat
[144] Opus Genetics, Inc. SEC Filing - Stock Titan
Opus Genetics (IRD) Initiates Coverage with Outperform Rating by Oppenheimer | IRD Stock News - GuruFocus
Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD) - MarketBeat
Oppenheimer Analyst Initiates Coverage on Opus Genetics (IRD) wi - GuruFocus
Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
There's Reason For Concern Over Opus Genetics, Inc.'s (NASDAQ:IRD) Massive 26% Price Jump - 富途牛牛
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Biotechnology company Opus Genetics Inc recently filed documents with the U.S. Securities and Exchange Commission (SEC) to officially register 7.4 million shares of common stock for secondary market resale. - Bitget
[S-3] Opus Genetics, Inc. Shelf Registration Statement | IRD SEC FilingForm S-3 - Stock Titan
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
HC Wainwright Has Negative View of Opus Genetics Q1 Earnings - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Opus Genetics - MarketBeat
BTIG raises its price target on Opus Genetics, Inc. (IRD) to $12 from $7 and maintains a buy rating - MSN
Opus Genetics, Inc. 2025 Annual Report: Gene Therapy Pipeline, Clinical Progress, and Strategic Partnerships in Ophthalmology - Minichart
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Opus Genetics (NASDAQ:IRD) Given New $10.00 Price Target at Wedbush - MarketBeat
Opus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Chardan Capital Analyst Says - MarketBeat
Opus Genetics (IRD) Target Price Raised by Wedbush Analyst | IRD Stock News - GuruFocus
Chardan Capital Raises Price Target for Opus Genetics (IRD) to $11 | IRD Stock News - GuruFocus
Opus Genetics (IRD) Gets a Buy from H.C. Wainwright - The Globe and Mail
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating - Insider Monkey
Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026 - Meyka
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target By Investing.com - Investing.com India
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target - Investing.com Australia
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):